US Health Experts Vote in Favor of Approving New Obesity Drug

by Sheela Philomena on  February 23, 2012 at 9:52 AM Drug News
RSS Email Print This Page Comment
Font : A-A+

An advisory panel of health experts to FDA urged approval of a new obesity drug - Qnexa. The panel voted 20-2 that the FDA should allow Qnexa on the market, saying the latest overall benefit-risk assessment supported its approval.
 US Health Experts Vote in Favor of Approving New Obesity Drug
US Health Experts Vote in Favor of Approving New Obesity Drug

The drug, made by California-based biotech firm Vivus, is the first obesity drug submitted to the FDA in more than a decade.

Qnexa combines two existing drugs, the appetite suppressant phentermine and topiramate, an anti-convulsant that can be used in conjunction with other drugs for weight loss.

The FDA does not have to follow the advice of the advisory panel, though it usually does. A final decision is expected by April 17.

Source: AFP

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Related Links

More News on:

Bariatric Surgery Drug Toxicity Obesity Diabetes - Essentials Binge Eating : The Pleasure and Pain Bulimia Nervosa Body Mass Index Signature Drug Toxicity Liposuction Battle of the Bulge 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive